Countrymen can soon get relief from the havoc of Corona infection. Adar Poonawalla, CEO of the Serum Institute of India (SII), which is developing the Corona Vaccine in association with Oxford University, says that the emergency use of the Corona vaccine may be allowed in the country by the end of this month.
The vaccination campaign can begin in India in January. Adar Poonawala said at a Global Business Summit that it is expected that by the end of this month, SII may get a license for emergency use of the vaccine, but will get permission for its use later. He is confident that the vaccination campaign against Corona will start in India from January 2021 as soon as the regulatory approval is granted. SII is developing the Corona vaccine in association with Oxford University.
Poonawala said that his company is preparing the Corona vaccine dose for the government as well as the private market. The central government wants to buy 30 to 40 crore doses of the vaccine by July next year. The Union Ministry of Health and Family Welfare plans to give the anti-coronary vaccine to 20 to 30 percent of the country's population. He expressed the possibility that by October next year, most of the country's population would be vaccinated with the corona vaccine. Only then life will be normal.
'Vaccine will be available to everyone by September and October next year'
Poonawalla said that it is not yet clear about the corona vaccine whether the vaccine is able to protect the person from the virus infection and prevent the spread of the infection. Poonawala said that he does not even know about it yet. Only when 20 percent of the country's population gets vaccinated with the corona vaccine, will the confidence return and the perception will be strong. It is expected that by September and October next year, the vaccine will be available to everyone and life will become normal.
SII's partnership with Oxford University
The Serum Institute of India has partnered with global pharmaceutical company AstraZeneca and Oxford University for the Corona vaccine. Interim results of the Phase III trial of the Kovid-19 pandemic vaccine were released some time ago. Early indications were that this vaccine could reduce the spread of the virus in cases of untreated infection. The vaccine has been, on average, 70% effective, based on a combined analysis of two trials. In India, this vaccine is named Kovishield.